Leerink Partnrs Issues Negative Forecast for MREO Earnings

Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) – Leerink Partnrs cut their Q4 2025 earnings estimates for shares of Mereo BioPharma Group in a research note issued on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of $0.04 per share for the quarter, down from their previous forecast of $0.05. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Several other equities analysts have also weighed in on MREO. Zacks Research lowered Mereo BioPharma Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mereo BioPharma Group in a research report on Wednesday, October 8th. Wall Street Zen upgraded Mereo BioPharma Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, JPMorgan Chase & Co. upped their target price on Mereo BioPharma Group from $7.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Mereo BioPharma Group currently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Mereo BioPharma Group Stock Performance

Shares of Mereo BioPharma Group stock opened at $1.84 on Wednesday. The firm has a 50-day simple moving average of $1.91 and a two-hundred day simple moving average of $2.09. Mereo BioPharma Group has a fifty-two week low of $1.47 and a fifty-two week high of $4.21. The company has a market cap of $292.56 million, a P/E ratio of -30.67 and a beta of 0.41.

Mereo BioPharma Group (NASDAQ:MREO) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $3.70 million.

Institutional Trading of Mereo BioPharma Group

Institutional investors have recently made changes to their positions in the company. Atle Fund Management AB boosted its stake in Mereo BioPharma Group by 96.1% during the 2nd quarter. Atle Fund Management AB now owns 764,901 shares of the company’s stock worth $2,073,000 after purchasing an additional 374,901 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Mereo BioPharma Group by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock valued at $4,783,000 after buying an additional 6,068 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in shares of Mereo BioPharma Group by 53.4% in the first quarter. Frazier Life Sciences Management L.P. now owns 7,819,863 shares of the company’s stock worth $17,595,000 after buying an additional 2,722,084 shares in the last quarter. Aberdeen Group plc acquired a new position in Mereo BioPharma Group during the first quarter worth about $4,924,000. Finally, Significant Wealth Partners LLC boosted its position in Mereo BioPharma Group by 61.7% during the second quarter. Significant Wealth Partners LLC now owns 22,261 shares of the company’s stock worth $60,000 after acquiring an additional 8,490 shares during the last quarter. 62.83% of the stock is owned by institutional investors and hedge funds.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.